COVID-19 intensive care mortality in Sweden lower than in many studies from other countries

February 01, 2021

New research reveals that the COVID-19 intensive care (ICU) mortality rate in Sweden was lower during the first wave of the pandemic than in many studies from other countries. And while analysis of individual underlying conditions found they were linked to mortality, an analysis looking at all these variables together found COVID-19 mortality in intensive care was not associated with underlying conditions, except for chronic lung disease. This new study did, however, find that, like previous research, mortality was driven by age, severity of COVID-19 disease and the presence and extent of organ failure.

The study is published in the European Journal of Anaesthesiology (the official journal of the European Society of Anaesthesiology and Intensive Care [ESAIC]) and is by Dr Michelle Chew, Linkoping University Hospital, Linkoping, Sweden, and colleagues.

"Coupled with what is widely perceived to be a 'relaxed' national pandemic strategy, results for ICU care in Sweden are understandably under scrutiny," explain the authors.

They analysed 1563 adult admissions to Swedish ICUs from 6 March-6 May, 2020 with laboratory confirmed COVID-19 disease, and complete 30-day follow up, and found 30-day all-cause mortality was 27%, while mortality actually within ICU was 23%, indicating the most patients who died after requiring ICU treatment actually died within ICU.

Various factors including age were associated with mortality. Being male raised the risk of death by 50%, while having severe respiratory failure (more advanced disease -present in three quarters of patients) trebled the risk of death. However, except for chronic lung disease (a 50% increased risk of death), the presence of comorbidities was not independently associated with mortality. Also of note that was that the degree of hypoxia (insufficient oxygen) was much higher in this Swedish cohort than those from other countries. Put another way, these Swedish patients were generally sicker upon entering ICU.

The ICU mortality of 23% in this Swedish study is between that found in two nationwide studies with small cohorts from Iceland and Denmark, at 15% and 37% respectively. It is lower than the mortality rate reported from a North American study (35%) and a French-Belgian-Swiss study (26-30%). These studies had nearly complete discharge data, meaning that most patients had survived and left ICU or sadly died there, with few patients still being treated at the time of the study.

In one report from Lombardy, Italy, ICU mortality was initially reported to be 26%; however this did not contain complete data as many patients were still being treated. A later study consisting of mostly the same patients and with almost complete ICU follow-up, mortality was 49%. These results are comparable to a recent meta-analysis of 20 studies worldwide (TM Cook and colleagues, Anaesthesia, 2020) that reported an ICU mortality of 42% for patients with completed ICU admissions and discharge data. Another study by Cook and colleagues, being published in Anaesthesia at the same time as this Swedish study (see separate press release) shows global ICU mortality up to October 2020 has since dropped further to 36%.

This new study from Sweden confirms previous findings that mortality rates are significantly higher among those aged 65 years and older. Patients over 80 years of age were seven times more likely to die than those aged 50 years and under, although the authors make clear that their data "demonstrate that provision of intensive care should not be restricted on the basis of age alone". They add: "Not all over 80 year olds die in ICU, which is one reason why we cannot exclude this group of patients from ICU care based on age alone. All decisions on care must be taken on a patient-by-patient basis".

As in other studies, a majority of patients suffered from underlying conditions (comorbidities), most commonly high blood pressure, diabetes and obesity. Whilst most comorbidities were associated with death when analysed separately, their effects were not statistically significant after adjustment for other variables. Severe obesity (BMI>40) was not associated with increased mortality as suggested by other studies. The only underlying condition that was found to have an effect in Swedish patients was chronic lung disease, which was associated with a 50% increased risk of death.

The authors discuss the various aspects of the Swedish ICU policy that could be connected with the lower ICU mortality rate. They say: "We believe that process and organisational factors have likely contributed to the relatively good outcomes seen in Swedish ICUs as staffing, protective equipment, availability of drugs, medical and technical equipment were considered at an early stage at hospital and regional levels."

In the first quarter of 2020 Sweden had 5.1 ICU beds per 100,000 population, compared to 27/100,000 in the USA. The COVID-19 pandemic unleashed a coordinated response in Swedish ICUs doubling the number of beds from around 500 to more than 1100 at its peak. The proportion of occupied ICU beds in the country during the study period (the peak months of the first wave of the pandemic) never reached maximum capacity. Other factors potentially connected to lower COVID-19 ICU mortality are that anaesthesiology and intensive care are combined specialities in Sweden, and this dual competency enabled rapid diversion of resources from perioperative care to intensive care management.

However, Sweden's strategy has faced harsh criticism at home and abroad for being too relaxed and dependent on individual responsibility of citizens rather than enforced lockdowns. Sweden's King also, in late 2020, publicly criticised the country's COVID-19 strategy as a failure. New laws on public transport and gatherings were enacted in autumn 2020 to limit the rising spread of SARS-CoV-2, and in late 2020, the Swedish Government passed new laws in order to be able to enforce restrictions such as venue closures to prevent cases raging out of control. Future staffing shortages, the looming possibility of burn-out and numerous organisational challenges also remain.

The authors conclude: "Mortality rates in COVID-19 patients admitted to Swedish intensive care units are generally lower than previously reported in other countries despite more severe illness on admission among Swedish patients. Mortality appears to be driven by age, baseline disease severity, and the presence and degree of organ failure, rather than pre-existing comorbidities."

Professor Chew, who is also the deputy editor-in-chief of the European Journal of Anaesthesiology, adds: "Although Sweden chose a different pandemic strategy to its European neighbours, its population has not been immune to rising infection rates this winter. Only time will tell if the Swedish health care system can sustain the long-term burden of COVID-19 disease."

The European Society of Anaesthesiology and Intensive Care (ESAIC)

Related Mortality Articles from Brightsurf:

Being in treatment with statins reduces COVID-19 mortality by 22% to 25%
A research by the Universitat Rovira i Virgili (URV) and Pere Virgili Institut (IISPV) led by LluĂ­s Masana has found that people who are being treated with statins have a 22% to 25% lower risk of dying from COVID-19.

Mortality rate higher for US rural residents
A recent study by Syracuse University sociology professor Shannon Monnat shows that mortality rates are higher for U.S. working-age residents who live in rural areas instead of metro areas, and the gap is getting wider.

COVID-19, excess all-cause mortality in US, 18 comparison countries
COVID-19 deaths and excess all-cause mortality in the U.S. are compared with 18 countries with diverse COVID-19 responses in this study.

New analysis shows hydroxychloroquine does not lower mortality in COVID-19 patients, and is associated with increased mortality when combined with the antibiotic azithromycin
A new meta-analysis of published studies into the drug hydroxychloroquine shows that it does not lower mortality in COVID-19 patients, and using it combined with the antibiotic azithromycin is associated with a 27% increased mortality.

Hydroxychloroquine reduces in-hospital COVID-19 mortality
An Italian observational study contributes to the ongoing debate regarding the use of hydroxychloroquine in the current pandemic.

What's the best way to estimate and track COVID-19 mortality?
When used correctly, the symptomatic case fatality ratio (sCFR) and the infection fatality ratio (IFR) are better measures by which to monitor COVID-19 epidemics than the commonly reported case fatality ratio (CFR), according to a new study published this week in PLOS Medicine by Anthony Hauser of the University of Bern, Switzerland, and colleagues.

COVID-19: Bacteriophage could decrease mortality
Bacteriophage can reduce bacterial growth in the lungs, limiting fluid build-up.

COPD and smoking associated with higher COVID-19 mortality
Current smokers and people with chronic obstructive pulmonary disease (COPD) have an increased risk of severe complications and higher mortality with COVID-19 infection, according to a new study published May 11, 2020 in the open-access journal PLOS ONE by Jaber Alqahtani of University College London, UK, and colleagues.

Highest mortality risks for poor and unemployed
Large dataset shows that income, work status and education have a clear influence on mortality in Germany.

Addressing causes of mortality in Zambia
Despite the fact that people in sub-Saharan Africa are now living longer than they did two decades ago, their average life expectancy remains below that of the rest of the world population.

Read More: Mortality News and Mortality Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to